We further analyzed the relationship between their expression rates and clinical statuses, including newly diagnosed (ND, n = 12), resistant to lenalidomide (R, n = 3), resistant to bortezomib (Bor, n = 3), and resistant to both lenalidomide and bortezomib (RBor, n = 3), in the CD34+ MM population. This evidence concerns the gene CD34 and Miyoshi myopathy.